Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3Terminated 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Thoracic 1Breast 1

Conditions

Lymphoma, T-Cell, Cutaneous 5Lymphoma 5Lymphoma, T-Cell, Peripheral 4Leukemia, Lymphocytic, Chronic, B-Cell 4Sezary Syndrome 3Mycosis Fungoides 3Melanoma 3Lymphoma, Follicular 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms 3Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Leukemia 2Kidney Neoplasms 2Fallopian Tube Neoplasms 2Drug-Related Side Effects and Adverse Reactions 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Waldenstrom Macroglobulinemia 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Mastocytosis, Systemic 1Lymphoproliferative Disorders 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1

Interventions

Carboplatin 69Paclitaxel 63Cisplatin 32Topotecan 29Gemcitabine 21Docetaxel 20Cyclophosphamide 18Filgrastim 17liposomal doxorubicin 15Peripheral Blood Stem Cell Transplantation 15Bevacizumab 14sargramostim 11Taxes 10Drug Therapy 10Therapeutics 7Psychiatric Rehabilitation 7Immunohistochemistry 7Erlotinib Hydrochloride 7Amifostine 7Melphalan 6Chemotherapy, Adjuvant 6rucaparib 5pembrolizumab 5mirvetuximab soravtansine 5ixabepilone 5Surgical Procedures, Operative 5Mass Spectrometry 5Interleukin-12 Subunit p35 5Flow Cytometry 5Etoposide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Carcinoma, Ovarian Epithelial × denileukin diftitox × Clear all
NCT00357448 2019-05-14

Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer

University of Washington

Phase 1 Completed
11 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT00880360 2018-03-27

ONTAK

The University of Texas Health Science Center at San Antonio

Phase 2 Completed
19 enrolled 5 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT00228358 2014-11-11

Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine

University of Washington

Phase 1 Completed
8 enrolled
BreastGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡